Cytosorbents Financial Results
CytoSorbents reported Q3 2026 financial results, highlighting the achievement of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, while operating loss improved by 59% to $1.2 million due to disciplined cost management and improved gross margins.
- Term
- Q3 2026
“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”
Dr. Phillip Chan, Chief Executive Officer